Details for Patent: 7,687,073
✉ Email this page to a colleague
| Title: | Preparation of powder agglomerates |
| Abstract: | The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing. |
| Inventor(s): | Yang; Tsong-Toh (Warren, NJ) |
| Assignee: | Schering Corporation (Kenilworth, NJ) |
| Filing Date: | May 08, 2008 |
| Application Number: | 12/117,434 |
| Claims: | 1. A dosage form of a pharmacologically active agent useful for administration by oral inhalation therapy consisting essentially of: agglomerates of particles of at least one pharmacologically active agent, and particles of crystalline solid binder, said particles having an average particle size of 10 .mu.m or less and being provided in a weight ratio of between 100:1 to 1:500, wherein said agglomerates have a range in size from between about 100 and about 1500 .mu.m, and wherein said agglomerates are characterized by having a crush strength of between 50 mg and 5000 mg. 2. The dosage form of claim 1, wherein said particles of said pharmacologically active agent have an average particle size of 10 .mu.m or less. 3. The dosage form of claim 1, wherein said solid binder comprises at least one member selected from the group consisting of polyhydroxy aldehydes, polyhydroxy ketones, and amino acids. 4. The dosage form of claim 1, wherein said solid binder comprises a hydrated or anhydrous saccharide. 5. The dosage form of claim 1, wherein said solid binder comprises anhydrous lactose or a hydrated lactose. 6. The dosage form of claim 1, wherein said solid binder comprises anhydrous lactose. 7. The dosage form of claim 1, wherein said particles of said solid binder have an average particle size of 10 .mu.m or less. 8. The dosage form of claim 1, wherein said particles of pharmacologically active agent and said solid binder have been mixed to substantial homogeneity. 9. The dosage form of claim 1, wherein said particles of pharmacologically active agent and said solid binder have been agglomerated in a pan rotated with an eccentric motion. 10. The dosage form of claim 1, wherein said agglomerates have an average size of between about 300 and about 1000 .mu.m. 11. The dosage form of claim 1, wherein said agglomerates have a crush strength of between about 50 mg and about 5,000 mg after conversion of said convertible amorphous content. 12. The dosage form of claim 1, wherein said agglomerates have a crush strength of between about 200 mg and about 1,500 mg. 13. The dosage form of claim 1, wherein said pharmacologically active agent and said solid binder are mixed at a weight ratio of between about 1000:1 to 1:1000. 14. The dosage form of claim 1, wherein said pharmacologically active agent and said solid binder are mixed at a weight ratio of between about 100:1 to 1:500. 15. The dosage form of claim 1, wherein said pharmacologically active agent and said solid binder are mixed at a weight ratio of between about 100:1 to 1:300. 16. The dosage form of claim 1, wherein said pharmacologically active agent and said solid binder have been agglomerated at a weight ratio of between about 20:1 to about 1:20. 17. The dosage form of claim 1, wherein said pharmacologically active agent and said solid binder have been agglomerated at a weight ratio of between about 1:3 to about 1:10. |
